Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS-102 in Recurrent/Metastatic Nasopharyngeal Carcinoma
NCT04627961Phase 2Unknown
- Sponsor
- National University Hospital
- Start
- Aug 2020
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trifluridine + tipiracil in nasopharyngeal carcinoma (NPC), sponsored by National University Hospital. Primary endpoint: Disease Control Rate at 45 months. Status: unknown.
02
Drugs
trifluridine + tipiracil
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT04627961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04627961.